HMGB-1 AS A THERAPEUTIC TARGET FOR INFECTIOUS AND INFLAMMATORY DISORDERS

High-mobility group box (HMGB)-1 was recently identified as a lethal mediator of severe sepsis and represents a novel group of intracellular proteins that function as inflammatory cytokines when released into the extracellular milieu. From a clinical perspective, extracellular HMGB-1 can cause multiple organ failure and contribute to the pathogenesis of diverse disorders including sepsis, cardiovascular shock, rheumatoid arthritis, diabetes, and cancer. HMGB-1 has been proven to be a successful therapeutic target in experimental models of diverse infectious and inflammatory diseases, and these findings have renewed the clinical interest of specific cytokine inhibitors. However, little is known about the molecular mechanisms underlying the cytokine activity of HMGB-1 and its contribution to infection and inflammation. This article analyzes the value of HMGB-1 as a therapeutic target for the treatment of diverse infectious and inflammatory disorders and its interest for human clinical trials.

[1]  K. Tracey,et al.  Alpha-chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[2]  L. Ulloa.  The vagus nerve and the nicotinic anti-inflammatory pathway , 2005, Nature Reviews Drug Discovery.

[3]  M. Bianchi,et al.  HMGB1: guiding immunity from within. , 2005, Trends in immunology.

[4]  I. Douglas,et al.  HMGB1 contributes to the development of acute lung injury after hemorrhage. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[5]  K. Tracey,et al.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.

[6]  K. Tracey,et al.  Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. , 2005, Journal of lipid research.

[7]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[8]  Y. Taira,et al.  The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. , 2005, The Journal of surgical research.

[9]  K. Tracey,et al.  The "cytokine profile": a code for sepsis. , 2005, Trends in molecular medicine.

[10]  Masaki Tanaka,et al.  Contributions of high mobility group box protein in experimental and clinical acute lung injury. , 2004, American journal of respiratory and critical care medicine.

[11]  M. Fink,et al.  Ethyl Pyruvate Inhibits Nuclear Factor-κB-Dependent Signaling by Directly Targeting p65 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[12]  K. Tracey,et al.  Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis , 2004, Nature Medicine.

[13]  M. Matthay,et al.  Can nicotine treat sepsis? , 2004, Nature Medicine.

[14]  S. Müller,et al.  HMGB1 is an endogenous immune adjuvant released by necrotic cells , 2004, EMBO reports.

[15]  K. Tracey,et al.  HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. , 2004, Rheumatic diseases clinics of North America.

[16]  K. Tracey,et al.  Recombinant HMGB1 with cytokine-stimulating activity. , 2004, Journal of immunological methods.

[17]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[18]  K. Tracey,et al.  Extracellular role of HMGB1 in inflammation and sepsis , 2004, Journal of internal medicine.

[19]  E. Abraham,et al.  Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein* , 2004, Journal of Biological Chemistry.

[20]  K. Tracey,et al.  Lipid unites disparate syndromes of sepsis , 2004, Nature Medicine.

[21]  H. Suh,et al.  Therapeutic effects of lysophosphatidylcholine in experimental sepsis , 2004, Nature Medicine.

[22]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Fink,et al.  Ethyl Pyruvate Provides Durable Protection Against Inflammation-Induced Intestinal Epithelial Barrier Dysfunction , 2003, Shock.

[24]  Janet S. Lee,et al.  Cytokine-mediated inflammation in acute lung injury. , 2003, Cytokine & growth factor reviews.

[25]  Tiziana Bonaldi,et al.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion , 2003, The EMBO journal.

[26]  Peter A. Ward,et al.  Novel strategies for the treatment of sepsis , 2003, Nature Medicine.

[27]  M. Yamakuchi,et al.  High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. , 2003, Arthritis and rheumatism.

[28]  K. Tracey,et al.  Ethyl Pyruvate Protects against Lethal Systemic Inflammation by Preventing HMGB1 Release , 2003 .

[29]  P. Gregersen,et al.  High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. , 2003, Arthritis and rheumatism.

[30]  H. Kuniyasu,et al.  Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. , 2003, Oncology reports.

[31]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[32]  M. Bianchi,et al.  The nuclear protein HMGB1 is secreted by monocytes via a non‐classical, vesicle‐mediated secretory pathway , 2002, EMBO reports.

[33]  Jun Yu Li,et al.  High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. , 2002, Arthritis and rheumatism.

[34]  K. Tracey,et al.  Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Tracey,et al.  HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. , 2002, Gastroenterology.

[36]  G. Tiegs,et al.  Cytokine expression in three mouse models of experimental hepatitis. , 2002, Cytokine.

[37]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[38]  Yan Xu,et al.  Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. , 2002, Biochimica et Biophysica Acta.

[39]  W. Fang,et al.  The Significance of Changes in High Mobility Group-1 Protein mRNA Expression in Rats After Thermal Injury , 2002, Shock.

[40]  M. Fink,et al.  Ringer’s ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats , 2001, Critical care medicine.

[41]  E. Melloni,et al.  Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiation. , 2001, The Biochemical journal.

[42]  D. Brenner,et al.  NF-κB stimulates inducible nitric oxide synthase to protect mouse hepatocytes from TNF-α– and Fas-mediated apoptosis , 2001 .

[43]  T. Butler,et al.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.

[44]  K. Tracey,et al.  HMG-1 as a mediator of acute lung inflammation. , 2000, Journal of immunology.

[45]  K. Tracey,et al.  High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes , 2000, The Journal of experimental medicine.

[46]  R. Bucala,et al.  Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.

[47]  K. Tracey,et al.  Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock , 1999, The Lancet.

[48]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[49]  A. Aguzzi,et al.  The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice , 1999, Nature Genetics.

[50]  J. Massagué,et al.  Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway , 1999, Nature.

[51]  M. Yoshida,et al.  Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. , 1998, The Journal of rheumatology.

[52]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[53]  D. Brenner,et al.  NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. , 1998, The Journal of clinical investigation.

[54]  Y. Iwakura,et al.  Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. , 1997, Journal of immunology.

[55]  R. Barst,et al.  Primary pulmonary hypertension: immunogenetic response to high‐mobility group (HMG) proteins and histone , 1996, Clinical and experimental immunology.

[56]  L. Moldawer,et al.  BLOCKADE OF TUMOR NECROSIS FACTOR REDUCES LIPOPOLYSACCHARIDE LETHALITY, BUT NOT THE LETHALITY OF CECAL LIGATION AND PUNCTURE , 1995, Shock.

[57]  David Baltimore,et al.  Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses , 1995, Cell.

[58]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[59]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[60]  D. Remick,et al.  Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. , 1992, Journal of immunology.

[61]  H. Rauvala,et al.  Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. , 1991, The Journal of biological chemistry.

[62]  P. Ward,et al.  Role of C5a in inflammatory responses. , 2005, Annual review of immunology.

[63]  J. Massagué,et al.  Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. , 1999, Nature.

[64]  T. van der Poll,et al.  Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? , 1995, Shock.

[65]  M. Fritzler,et al.  Antibodies to HMG proteins in patients with drug-induced autoimmunity. , 1994, Arthritis and rheumatism.

[66]  T. Kislinger,et al.  Blockade of RAGE ± amphoterin signalling suppresses tumour growth and metastases , 2022 .